Syros Pharmaceuticals (SYRS) Misses Q2 EPS by 13c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 EPS of ($0.54), $0.13 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $6.28 million versus the consensus estimate of $4.74 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• FirstCash to acquire UK pawn operator Ramsdens for £206 million
• Robinhood prices $2B convertible notes offering due 2029